Drug discovery company Summit Therapeutics PLC (LON:SUMM) is set to present pre-clinical data from the University of Oxford highlighting the potential of its utrophin modulation programme in treating duchenne muscular dystrophy (DMD), a muscle wasting disease.
The company's scientific adviser and co-founder, Professor Kay Davies from the University of Oxford, will present the findings during presentations at the 15th Action Duchenne International Conference 2017 on November 10-12, 2017, in Birmingham, UK.
The data shows that continuously expressing utrophin in a dystrophin-deficient background can reduce mitochondrial aberration and oxidative stress, Summit said in a statement on Thursday.
Summit's own presentations will focus on the ongoing Phase II proof of concept clinical trial, PhaseOut DMD, which is evaluating its lead utrophin modulator, ezutromid.
PhaseOut DMD, a 48-week open-label clinical trial, has enrolled 40 patients with DMD.
The data for the first 24 weeks of the trial is expected to be reported in the first quarter of 2018 and Summit said this assessment could provide initial clinical proof of mechanism for ezutromid.
"We remain on-track to report the first results of ezutromid treatment in boys with DMD in PhaseOut DMD in the first quarter of 2018, and if results provide evidence of the mechanism of utrophin modulation in patients, we believe it would represent a major advancement for ezutromid,” said Dr David Roblin, chief operating officer and medical officer at Summit.
“It would bring closer to all patients a therapy that has the potential to be disease modifying in DMD."